MedPath

Feasibility of Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a pilot study.

Not Applicable
Conditions
corticosteroid-refractory graft-versus-host disease
Registration Number
JPRN-UMIN000021349
Lead Sponsor
Tohoku University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
2
Inclusion Criteria

Not provided

Exclusion Criteria

1) with active infection 2) w/o informed consent 3) CCr<10 ml/min

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
response rete of GVHD adverse effect
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath